Cite
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.
MLA
Di Federico, Alessandro, et al. “Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.” Cancers, vol. 14, no. 10, May 2022, p. 2429–N.PAG. EBSCOhost, https://doi.org/10.3390/cancers14102429.
APA
Di Federico, A., Mosca, M., Pagani, R., Carloni, R., Frega, G., De Giglio, A., Rizzo, A., Ricci, D., Tavolari, S., Di Marco, M., Palloni, A., & Brandi, G. (2022). Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes. Cancers, 14(10), 2429–N.PAG. https://doi.org/10.3390/cancers14102429
Chicago
Di Federico, Alessandro, Mirta Mosca, Rachele Pagani, Riccardo Carloni, Giorgio Frega, Andrea De Giglio, Alessandro Rizzo, et al. 2022. “Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes.” Cancers 14 (10): 2429–N.PAG. doi:10.3390/cancers14102429.